Psoriasis plaques on back and buttocks/Plaques returned after third dose of COVID Vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (Psoriasis plaques on back and buttocks/Plaques returned after third dose of COVID Vaccine) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Psoriasis.    Concurrent medical conditions included Psoriasis.   On 27-Jan-2021, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) 150 milligram. On 21-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Sep-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Feb-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PSORIASIS (Psoriasis plaques on back and buttocks/Plaques returned after third dose of COVID Vaccine) (seriousness criterion medically significant). At the time of the report, PSORIASIS (Psoriasis plaques on back and buttocks/Plaques returned after third dose of COVID Vaccine) had not resolved.            No concomitant medications were reported. No treatment drugs were reported.  The formulation for SKYRIZI was reported as Solution for injection.  It was reported that, two days after vaccine process of clearing skin from plaques stopped and remained plaques on upper back and buttocks that had not gone away. Knees were clear. reporter informed that skyriz's effectiveness had stopped.  The reporter's causality for the event(s) of psoriasis plaques on back and buttocks/plaques returned after third dose of COVID vaccine with Skyrizi (RISANKIZUMAB) was no reasonable possibility. The reporter's causality for the event(s) of stopped Skyriz's effectiveness was not provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company Comment: This spontaneous case concerns an adult, male patient of unknown age with a concurrent condition of psoriasis treated with Risankizumab, who experienced an unexpected, medically significant event of Psoriasis flare-up after receiving a 3rd dose of mRNA-1273 vaccine. Exact latency of the event relative to vaccination cannot be determined with unknown event's onset date. Reportedly, psoriasis plaques on his back and buttocks appeared post vaccination and risankizumab's effect stopped. Reportedly, plaques were cleared on his knees but remained on upper back and buttocks. Vaccination history included a 2-dose primary series of mRNA-1273 vaccine, given 11 days apart. Patient's underlying psoriasis and treatment with Risankizumab remain as confounders in this case. The benefit-risk relationship of mRNA-1273 is not affected by this report. Event's seriousness assessed based on medical judgement and the available information.   This case was linked to MOD-2022-628472 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 28-Jul-2022: Live-non significant follow-up received. narrative description updated.; Sender's Comments: This spontaneous case concerns an adult, male patient of unknown age with a concurrent condition of psoriasis treated with Risankizumab, who experienced an unexpected, medically significant event of Psoriasis flare-up after receiving a 3rd dose of mRNA-1273 vaccine. Exact latency of the event relative to vaccination cannot be determined with unknown event's onset date. Reportedly, psoriasis plaques on his back and buttocks appeared post vaccination and risankizumab's effect stopped. Reportedly, plaques were cleared on his knees but remained on upper back and buttocks. Vaccination history included a 2-dose primary series of mRNA-1273 vaccine, given 11 days apart. Patient's underlying psoriasis and treatment with Risankizumab remain as confounders in this case. The benefit-risk relationship of mRNA-1273 is not affected by this report. Event's seriousness assessed based on medical judgement and the available information.